Serina Therapeutics awarded multiple patents for its polymer drug delivery technology
HUNTSVILLE -- Serina Therapeutics, Inc., a pharmaceutical research and development company, announced the company was awarded two patents from the United States Patent and Trademark Office covering its polymer technology.
The patents entitled “Multi-armed forms of activated polyoxazoline and methods of synthesis thereof” (U.S. Patent No. 8,088,884) and “Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same” (U.S. Patent No. 8,110,651) cover the synthesis and composition of new scaffolds of polyoxazolines for the delivery of different types of drug molecules.
“These additional patent awards strengthen our polymer drug delivery platforms and add intellectual property support to our lead candidates currently in drug development,” said Michael D. Bentley, Ph.D., chief scientific officer and cofounder of the company.
The issue of these two patents is the result of years of groundbreaking research in the development of safe polyoxazoline polymers for drug delivery.
“We are now in a position to add to our strong pipeline of polymer therapeutic molecules,” said Bentley.
For more information on Serina Therapeutics, please visit serinatherapeutics.com
About Serina Therapeutics
Serina Therapeutics is a privately held pharmaceutical company that develops novel polymer therapeutics based on its proprietary polyoxazoline (POZ) technology platforms. The founders and managers of Serina were formerly the key principals of Shearwater Polymers, a company that enabled nine approved polyethylene glycol (PEG) products for various pharmaceutical partners. Besides developing its own pipeline of pharmaceutical products, Serina is also partnering its technology with pharmaceutical companies to develop high value products addressing unmet clinical needs. Serina Therapeutics is located with the HudsonAlpha Institute for Biotechnology in Huntsville, Ala.